For many allergic patients sedation is the most severe side effect of
antihistamine treatment. The reduction of this attribute is a major ob
jective of drug development. Topical application of antihistamines wit
h known sedative potential may be a solution to the problem. In compar
ative clinical double blind studies using the new H-1 receptor antagon
ist Azelastine which was applied topically as nasal spray, no sedation
was detected. These studies carried out in the years 1992 and 1993 by
our department included 806 patients suffering from seasonal allergic
rhinitis. It was found that patients' vigilance increased under treat
ment.